Tag Archives: disease

Ardelyx’s kidney disease drug reduces elevated phosphate levels in late-stage study

(Reuters) – Ardelyx Inc said on Tuesday its experimental drug succeeded in regulating elevated blood phosphate levels in patients with chronic kidney disease (CKD) in a late-stage study. The treatment, tenapanor, showed a greater difference in serum phosphorus levels compared to placebo, the company said. Elevated phosphorus levels are common in CKD patients, especially those… Read More »

FDA Approves Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease

FDA Approves Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease Print this page SOUTH SAN FRANCISCO, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) —  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta™ (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children… Read More »

Rates of pneumonia and pneumococcal disease remain high among people with HIV

The incidence of invasive pneumococcal disease and community-acquired pneumonia remains high among people living with HIV, investigators from the Netherlands report in Clinical Infectious Diseases. Rates of these serious lung infections were highest among people not taking anti-HIV drugs and with CD4 cell count below 500. Incidence was also much higher than that seen in the… Read More »

Scientists uncover the process behind protein mutations that impact gut health, Crohn’s Disease and inflammatory bowel disease

By Ana Gajic A new study led by researchers at St. Michael’s Hospital and the Princess Margaret Cancer Centre in Canada and Zhejiang University School of Medicine in China has uncovered why a protein mutation that causes inflammatory bowel diseases is dysfunctional. Published today in Science, the research focused on nucleotide-binding oligomerization domain-containing protein 1 and… Read More »

FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

Print this page SUMMIT, N.J.–(BUSINESS WIRE) July 19, 2019 — Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the… Read More »